Abstract
Background
Recent studies of conventional chemotherapeutic drugs administered in metronomic therapy schedules showed remarkable inhibitory effects on tumor angiogenesis. Subsequent and prolonged tumor regression was achieved moreover by circumventing acquired drug resistance. In this study, metronomic and conventional trofosfamide were compared on human NSCLC xenograft “LX-1.”
Materials and methods
In vitro cytotoxicity of trofosfamide on tumor and human umbilical cord endothelial cells was determined under normoxic and hypoxic conditions. Additionally fractions and duration of cell cycles were analyzed by flow cytometry. In vivo LX-1 xenotransplanted nude mice were treated with trofosfamide in conventional and metronomic schedules (i.p./p.o.). Tumor sections were evaluated for microvessel density (MVD), relative growth fraction and apoptosis.
Results
In contrast to the rapid growth of conventionally treated lung cancer, long lasting tumor growth retardation over the total treatment period was achieved with metronomic treatment. While growth fraction and apoptotic rate of LX-1 cells remained unchanged, the MVD was significantly reduced (50%).
Conclusion
Our results show advantages of a metronomic trofosfamide schedule compared to a conventional bolus therapy mainly due to inhibition of angiogenesis. In vitro data show that this mechanism works under normoxic and hypoxic conditions and suggest that this is in part a direct cytotoxic effect on endothelial cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Al-Batran SE, Atmaca A, Bert F, Jager D, Frisch C, Neumann A, Orth J, Knuth A, Jager E (2004) Dose escalation study for defining the maximum tolerated dose of continuous oral trofosfamide in pretreated patients with metastatic lung cancer. Onkologie 27:534–538
Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 27:482–487
Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342–4346
Bocci G, Nicolaou KC, Kerbel RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62:6938–6943
Bocci G, Francia G, Man S, Lawler J, Kerbel RS (2003) Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100:12917–12922
Boos J, Kupker F, Blaschke G, Jurgens H (1993) Trofosfamide metabolism in different species—ifosfamide is the predominant metabolite. Cancer Chemother Pharmacol 33:71–76
Brinker A, Kisro J, Letsch C, Bruggemann SK, Wagner T (2002) New insights into the clinical pharmacokinetics of trofosfamide. Int J Clin Pharmacol Ther 40:376–381
Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886
Falkson G, Falkson HC (1978) Trofosfamide in the treatment of patients with cancer. A pilot trial. S Afr Med J 53:886–888
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186
Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493–501
Gunsilius E, Gierlich T, Mross K, Gastl G, Unger C (2001) Palliative chemotherapy in pretreated patients with advanced cancer: oral trofosfamide is effective in ovarian carcinoma. Cancer Invest 19:808–811
Hammers HJ, Kirchner H, Schlenke P (2000) Ultraviolet-induced detection of halogenated pyrimidines: simultaneous analysis of DNA replication and cellular markers. Cytometry 40:327–335
Hartmann JT, Oechsle K, Mayer F, Kanz L, Bokemeyer C (2003) Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res 23:1899–1901
Horvath V, Hartlapp JH, Hegewisch-Becker S, Feyerabend T, Fischer v. Weikersthal L, Illiger HJ, Jäger E, Peters SO, Reichardt P, Uthgenannt D, Weber K, Wagner T, Wiedemann G, Zschaber R (2000) Oral trofosfamide in elderly and/or heavily pretreated patients with metastatic lung cancer. Onkologie 23:341–344
Jaffe EA, Nachman RL, Becker CG, Minick CR (1973) Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52:2745–2756
Jahnke K, Bechrakis NE, Coupland SE, Schmittel A, Foerster MH, Fischer L, Thiel E, Korfel A (2004) Treatment of primary intraocular lymphoma with oral trofosfamide: report of two cases and review of the literature. Graefes Arch Clin Exp Ophthalmol 242(9):771–776
Joussen AM, Kruse FE, Volcker HE, Kirchhof B (1999) Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol 237:920–927
Kerbel RS, Klement G, Pritchard KI, Kamen B (2002) Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 13:12–15
Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, Hicklin D, Kerbel RS (2002) Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 8:221–232
Kueng W, Silber E, Eppenberger U (1989) Quantification of cells cultured on 96-well plates. Anal Biochem 182:16–19
Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS (2002) Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62:2731–2735
Miller KD, Sweeney CJ, Sledge GW Jr (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19:1195–1206
Ormerod MG, Payne AW, Watson JV (1987) Improved program for the analysis of DNA histograms. Cytometry 8:637–641
Sasaki K, Adachi S, Yamamoto T, Murakami T, Tanaka K, Takahashi M (1988) Effects of denaturation with HCl on the immunological staining of bromodeoxyuridine incorporated into DNA. Cytometry 9:93–96
Schmidt-Sandte W, Dageforde J, Klapdor R, Wagner T, Wiedemann GJ (1999) Trofosfamide in patients with pancreatic cancer. Anticancer Res 19:2485–2487
Shizukuda Y, Helisch A, Yokota R, Ware JA (1999) Downregulation of protein kinase cdelta activity enhances endothelial cell adaptation to hypoxia. Circulation 100:1909–1916
Vogt T, Hafner C, Bross K, Bataille F, Jauch KW, Berand A, Landthaler M, Andreesen R, Reichle A (2003) Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 98:2251–2256
Wagner A, Hempel G, Boos J (1997) Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 8:419–431
Yu JL, Coomber BL, Kerbel RS (2002) A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation 70:599–609
Acknowledgments
We thank Monica Vollmert for her invaluable assistance and Dr Clemens Engels for supporting our immunohistochemical studies.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Klink, T., Bela, C., Stoelting, S. et al. Metronomic trofosfamide inhibits progression of human lung cancer xenografts by exerting anti-angiogenic effects. J Cancer Res Clin Oncol 132, 643–652 (2006). https://doi.org/10.1007/s00432-006-0112-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-006-0112-x